๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

โœ Scribed by Pardanani, A; Vannucchi, A M; Passamonti, F; Cervantes, F; Barbui, T; Tefferi, A

Book ID
109887302
Publisher
Nature Publishing Group
Year
2010
Tongue
English
Weight
316 KB
Volume
25
Category
Article
ISSN
0887-6924

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Evaluating the serial use of the myelofi
Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement : Performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
โœ Ruben A. Mesa; Hagop Kantarjian; Ayalew Tefferi; Amylou Dueck; Richard Levy; Kri ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 264 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND: Symptomatic burden from constitutional symptoms, anemia, and splenomegalyโ€related symptoms are common and morbidity inducing in patients with myelofibrosis (MF). The authors previously developed a MFโ€specific instrument for capturing the burden of MFโ€associated diseaseโ€r